drugset / Trial / NCT05409261
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase 2
Unknown
200 enrolled
ANRS, Emerging Infectious Diseases
APHP · collabCEPI · collabCenter for Vaccine Development - Mali · collabInnovative clinical research network in vaccinology (IREIVAC) · collabInstitut National de la Santé Et de la Recherche Médicale, France · collab
NaSingle-groupOpen-labelPrevention
Summary
Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete vaccination schedule of SARS-CoV-2 vaccine.
Timeline
- Start
- 2022-06-02
- Primary completion
- 2022-09-25
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad26.COV2.S | Vaccine | 0.5 ml | Intramuscular |